Legal
The decision, which is likely to be appealed, will allow Dana-Farber to license the technology.
The plaintiffs allege that Gilead and other companies used anticompetitive tactics to keep prices artificially high for their respective HIV treatments.
Purdue, Bristol-Myers Squibb and Apotex have been singled out in opioid-related lawsuits in Canada.
Bayer said the award conflicts with an April report from the EPA that says glyphosate, the active ingredient in Roundup, is not a carcinogen.
Insys owes more than $240 million in legal-related fees but the company only has about $87 million in available cash.
The two generic drugmakers, along with many others, have been accused of conspiring to inflate the price of more than 100 generic drugs.
Companies that generate revenue less than $100 million would not have to undergo regular outside audits.
Johnson & Johnson has lost several major lawsuits over allegations that asbestos in its talcum powder contributes to ovarian cancer.
Today has been marked by a wide range of life science and biopharma stories. Here’s a broader look at some of the top stories.
Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.
PRESS RELEASES